The "Miracle Marijuana" Breakthrough Wooing Big Pharma

With testing underway, one medical marijuana breakthrough could tempt some major pharma players.

The medical marijuana industry is creating massive opportunities for forward-thinking investors. The global market is estimated to be worth $7.7 billion, and will potentially see a compound annual growth rate of 60 percent, as other countries continue to liberalize their medical marijuana laws. Grand View Research has predicted that the global legal marijuana market is expected to reach a staggering $146.5 billion by the end of 2025.

Over the years, researchhas shown that marijuana is beneficial in the treatment of many conditions, including cancer, multiple sclerosis, epilepsy, arthritis, anxiety, IBS, and PTSD - creatinghuge opportunities for savvy companies (and savvy investors) to cash in on the craze, and one major marijuana player in particular is increasingly coming to the forefront of the industry.

Founded by world-class scientists from the University of Oxford, this company is leading the way with breaking research, including the discovery of an endogenous molecule that primes the body's own stem cells from a diverse range of tissues to accelerate repair and regeneration following acute or chronic injury.

The discovery is already undergoing testing in animal models of diseases, and no other comparative treatments exist - making this company a viable candidate for takeover by any number of Big Pharma players. What's more, the company already has preliminary data for myocardial infarction (heart attack) and are starting experiments in a model of type 1 diabetes.

With marijuana increasingly in the limelight, breakthroughs like this are sure to have Wall Street investors buzzing - and soon.

Click here to find out more about this promising "Miracle Marijuana" company, and how early investors can set themselves up to cash in on this unique medical breakthrough.